Clinical Trials Browser

Phase 1/2 × anetumab ravtansine × 90 days × Clear all

NCT03126630 2026-04-01

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Phase 1/2 Active not recruiting

49 enrolled 20 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant